TEQCoolAB Logo

MARKET

A Game-Changer in Brain Temperature Management

There is a critical, global need for advanced technologies that reduce brain metabolism and oxygen demand—a critical factor in life-threatening conditions such as:

Play Video
  • Traumatic Brain Injury (TBI) – $13.7 B market by 2030
  • Status Epilepticus (SE) – part of the $2.1 B epilepsy market by 2030
  • Subarachnoid Hemorrhage (SAH) – $4.2 B market by 2030
  • Stroke (Ischemic & Hemorrhagic) – $61.7 B market by 2030
  • Neonatal Hypoxic-Ischemic Encephalopathy (HIE) – $1.9 B market by 2030

 

While no dedicated standalone market exists for targeted brain temperature reduction, related segments are already thriving:

  • Brain Metabolism Reduction Therapies: $3.5 B by 2030.
  • Temperature Management (warming & cooling): $5.21 B by 2030.
  • Therapeutic Hypothermia: $0.48 B by 2030.

 

Each of these distinct, multi-billion-dollar markets underscores the appetite for better neuroprotection. In conversations with leading neurosurgeons and ICU specialists, the feedback is unanimous: if a precise, non-invasive brain-cooling solution existed, they would use it—but until now, nothing like TEQCool has existed.

Today, TEQCool fills that void—offering the first targeted intranasal system to lower metabolism, control oxygen demand, and prevent secondary injury in the most critical moments. TEQCool’s technology is perfectly positioned to transform existing fields where lowering brain metabolism is already recognized as critical.

Brain metabolism and oxygen demand reduction related markets

Temperature management global market

Therapeutic Hypothermia global market

TEQCool: A breakthrough solution

TEQCool revolutionizes brain cooling by offering a direct, non-invasive, and highly targeted approach. Unlike traditional cooling systems, TEQCool rapidly and selectively cools the brain via the nasal cavity, leveraging the body’s natural heat exchange system. This enables:

Current solutions fall short

These limitations create a clear and urgent need for a faster, safer, and more targeted solution—which is exactly what TEQCool delivers.

The TEQCool Value Proposition

TEQCool is redefining brain protection with a breakthrough technology that delivers rapid, precise, non-invasive brain cooling—meeting a critical unmet need in neurocritical care.

TEQCool isn’t just another cooling device—it’s a paradigm shift in brain protection, offering a smarter, faster, and efficient solution to one of the most pressing challenges in critical care medicine.

Commercialization roadmap

 

The TEQCool system will be launched in phases, starting with a research-use-only (RUO) version, which will be FDA-approved/CE-marked for clinical trials and early adopters. This phased approach allows for the collection of crucial clinical data and user feedback.

TEQCool’s non-invasive capabilities will address critical medical needs and have a significant impact on improving patient outcomes. The project’s phased development, combined with the expertise of key partners, positions TEQCool for a successful market introduction, transforming neurocritical care and setting the stage for future expansion into other patient groups.

Roadmap TEQCool